Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Folic acid + 5-Fluorouracil + Irinotecan + Oxaliplatin
FOLFIRINOX
Routinely available
Local application
29/03/2023
Indication
For use in palliative chemotherapy for inoperable pancreatic adenocarcinoma in good performance status patients.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available
Formulation
Combination chemotherapy
Comments
-